Laparoscopic prostatectomy for severely symptomatic, treatment-refractory chronic prostatitis: Preliminary observations from an ongoing phase II clinical trial

Arnon Krongrad, Shenghan Lai

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: We report outcomes 1 year after surgery for the first 6 consecutive patients enrolled in an ongoing, prospective, Phase II clinical trial of laparoscopic radical prostatectomy (LRP) as a treatment for severely symptomatic, treatment-refractory chronic prostatitis. The protocol is approved by the Western Institutional Review Board and listed on the searchable National Institutes of Health clinical trials Web site. METHODS: Patients met prespecified eligibility criteria, were fully counseled before treatment, gave written informed consent, had surgery, and were regularly monitored after treatment. The primary outcome measure was symptom severity, which was measured prior to LRP and at 1, 3, 6, and 12 months after treatment using the Chronic Prostatitis Symptom Index (CPSI). The exact Wilcoxon signed rank test was used to compare pretreatment and 6-month posttreatment scores, with statistical significance at P

Original languageEnglish (US)
JournalUroToday International Journal
Volume4
Issue number2
DOIs
StatePublished - Apr 2011

Fingerprint

Prostatitis
Phase II Clinical Trials
Prostatectomy
Therapeutics
Research Ethics Committees
National Institutes of Health (U.S.)
Nonparametric Statistics
Informed Consent
Outcome Assessment (Health Care)
Clinical Trials

Keywords

  • Chronic prostatitis
  • Clinical trial
  • Laparoscopic radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

@article{e695f348492c4dcfafa8bc9b04a3527c,
title = "Laparoscopic prostatectomy for severely symptomatic, treatment-refractory chronic prostatitis: Preliminary observations from an ongoing phase II clinical trial",
abstract = "INTRODUCTION: We report outcomes 1 year after surgery for the first 6 consecutive patients enrolled in an ongoing, prospective, Phase II clinical trial of laparoscopic radical prostatectomy (LRP) as a treatment for severely symptomatic, treatment-refractory chronic prostatitis. The protocol is approved by the Western Institutional Review Board and listed on the searchable National Institutes of Health clinical trials Web site. METHODS: Patients met prespecified eligibility criteria, were fully counseled before treatment, gave written informed consent, had surgery, and were regularly monitored after treatment. The primary outcome measure was symptom severity, which was measured prior to LRP and at 1, 3, 6, and 12 months after treatment using the Chronic Prostatitis Symptom Index (CPSI). The exact Wilcoxon signed rank test was used to compare pretreatment and 6-month posttreatment scores, with statistical significance at P",
keywords = "Chronic prostatitis, Clinical trial, Laparoscopic radical prostatectomy",
author = "Arnon Krongrad and Shenghan Lai",
year = "2011",
month = "4",
doi = "10.3834/uij.1944-5784.2011.04.12",
language = "English (US)",
volume = "4",
journal = "UroToday International Journal",
issn = "1939-4810",
publisher = "UroToday Inc.",
number = "2",

}

TY - JOUR

T1 - Laparoscopic prostatectomy for severely symptomatic, treatment-refractory chronic prostatitis

T2 - Preliminary observations from an ongoing phase II clinical trial

AU - Krongrad, Arnon

AU - Lai, Shenghan

PY - 2011/4

Y1 - 2011/4

N2 - INTRODUCTION: We report outcomes 1 year after surgery for the first 6 consecutive patients enrolled in an ongoing, prospective, Phase II clinical trial of laparoscopic radical prostatectomy (LRP) as a treatment for severely symptomatic, treatment-refractory chronic prostatitis. The protocol is approved by the Western Institutional Review Board and listed on the searchable National Institutes of Health clinical trials Web site. METHODS: Patients met prespecified eligibility criteria, were fully counseled before treatment, gave written informed consent, had surgery, and were regularly monitored after treatment. The primary outcome measure was symptom severity, which was measured prior to LRP and at 1, 3, 6, and 12 months after treatment using the Chronic Prostatitis Symptom Index (CPSI). The exact Wilcoxon signed rank test was used to compare pretreatment and 6-month posttreatment scores, with statistical significance at P

AB - INTRODUCTION: We report outcomes 1 year after surgery for the first 6 consecutive patients enrolled in an ongoing, prospective, Phase II clinical trial of laparoscopic radical prostatectomy (LRP) as a treatment for severely symptomatic, treatment-refractory chronic prostatitis. The protocol is approved by the Western Institutional Review Board and listed on the searchable National Institutes of Health clinical trials Web site. METHODS: Patients met prespecified eligibility criteria, were fully counseled before treatment, gave written informed consent, had surgery, and were regularly monitored after treatment. The primary outcome measure was symptom severity, which was measured prior to LRP and at 1, 3, 6, and 12 months after treatment using the Chronic Prostatitis Symptom Index (CPSI). The exact Wilcoxon signed rank test was used to compare pretreatment and 6-month posttreatment scores, with statistical significance at P

KW - Chronic prostatitis

KW - Clinical trial

KW - Laparoscopic radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=79955718049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955718049&partnerID=8YFLogxK

U2 - 10.3834/uij.1944-5784.2011.04.12

DO - 10.3834/uij.1944-5784.2011.04.12

M3 - Article

AN - SCOPUS:79955718049

VL - 4

JO - UroToday International Journal

JF - UroToday International Journal

SN - 1939-4810

IS - 2

ER -